ANÁLISE DA SEGURANÇA E EFICÁCIA DO USO DO CANABIDIOL PARA O TRANSTORNO DO ESPECTRO AUTISTA
ANALYSIS OF THE EFFICACY AND SAFETY OF CANNABIDIOL USE IN AUTISM SPECTRUM DISORDER
Abstract
ABSTRACT
Autism Spectrum Disorder (ASD) poses clinical challenges in managing disruptive behaviors and comorbidities due to the narrow therapeutic window of traditional psychopharmaceuticals. The objective of this study was to analyze recent scientific evidence regarding the efficacy and safety of cannabidiol (CBD) in the treatment of symptoms associated with ASD. The methodology was based on Cochrane guidelines and the PRISMA protocol, utilizing RoB 2.0 and ROBINS-I tools to evaluate randomized controlled trials (RCTs) and systematic reviews indexed in PubMed, EMBASE, and Cochrane. The results demonstrated that CBD-rich cannabis extracts promote statistically significant improvements in social responsiveness, interpersonal interaction, and anxiety reduction, with a favorable safety profile and mild adverse effects (somnolence and decreased appetite) in up to 9.7% of patients. It is concluded that CBD shows promising efficacy as an adjuvant therapy for specific refractory symptoms, although methodological heterogeneity and the absence of Phase 3 trials limit its universal clinical recommendation in supplementary health.
Keywords: Cannabidiol. Autism Spectrum Disorder. Health Technology Assessment. Supplemental Health.
Copyright (c) 2026 Luciana Biacchi Bond Honaiser Bastos, Luiz Henrique Picolo Furlan, Roberta Garcia Cjarello Ossoski, Eduardo Rocker Ramos, Jaquelin Lourenço Gomes

This work is licensed under a Creative Commons Attribution 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 Internacional Licence. 

.png)
